The expression pattern of the laminin-binding a7(31 integrin is developmentally regulated in skeletal, cardiac, and smooth muscle. The X1/X2 alternative splicing in the extracellular domain of a7 is found in the variable region between conserved a-chain homology repeat domains III and IV, a site implicated in ligand binding. To assess differences in X1/X2 isoform activity, we generated MCF-7 cell lines transfected with a7-X1 /X2 cDNAs. Transfectants expressing the a7-X2 variant adhered rapidly to laminin 1, whereas those expressing a7-X1 failed to attach. That a7-X1 exists in an inactive state was established in assays using an activating (31 antibody that induced X1-dependent cell adhesion and spreading. Furthermore, the activation of a7-X1 was cell type specific, and when expressed in HT1080 cells, the integrin was converted into a fully functional receptor capable of promoting adhesion. Thus, the expression of the a7-X1/X2 integrin is a novel mechanism that regulates receptor affinity states in a cell-specific context and may modulate integrin-dependent events during muscle development and repair.
INTRODUCTION
Integrins are members of a large family of cell surface receptors that mediate adhesive interactions with extracellular matrix macromolecules (Hynes, 1992) .
Numerous studies have indicated that integrins are dynamically regulated, existing in a relatively nonfunctional state in which they are incompetent to bind ligand or in a fully active ligand bound form (Diamond and Springer, 1994; Humphries, 1996;  Mould, 1996) . Frequently, the ligand-binding regions of integrin subunits are cryptic and only become exposed when the subunit has been activated. A number of factors, originating from outside the cell or from the cell interior, can shift the inactive extracellular conformation of the integrin to an active one. For example, antibodies that stimulate integrin function have been shown to bind the extracellular domain of the (31 subunit (Takada and Puzon, 1993; Diamond and Springer, 1994; Humphries, 1996; Mould, 1996) . These ligand interactions. For example, Mn2' and Mg2+ can promote ligand binding, whereas Ca2' acts as an inhibitor for a number of the integrin complexes (Humphries, 1996; Sanchez-Mateos et al., 1996) . Because integrin ligand recognition sites lie at or near the divalent cation binding regions, it has been proposed that divalent cations can directly induce a conformational change that exposes the ligand binding sites (Mould, 1996) .
In contrast to external factors such as cations and stimulating antibodies, other effectors can activate integrin subunits intracellularly. For example, phorbol esters, by simulating the protein kinase C pathway, can increase the adhesiveness of several cell types through specific integrins (Shimizu et al., 1990; Diamond and Springer, 1994) . Finally, activation of cer-tain integrins is dependent on cell-type-specific regulation (Chan and Hemler, 1993) that may be due to posttranslational modifications, variations in the sequences of the a or ,B subunits, and/or the activation of different signal transduction molecules (Chan and Hemler, 1993; Hughes et al., 1997) .
Additional complexity of integrin regulation is exemplified by that fact that integrin subunits can be alternatively spliced. This alternative splicing has been shown to occur not only in a number of mammalian a and (3 subunits but also in Drosophila integrin receptors (Brown et al., 1989; van Kuppevelt et al., 1989; Suzuki and Naitoh, 1990; Cooper et al., 1991; Hogervorst et al., 1991; Tamura, et al., 1991; Languino and Ruoslahti, 1992; Collo et al., 1993; Song et al., 1993; Ziober et al., 1993; Djaffar et al., 1994; Delwel et al., 1995; Meredith et al., 1995; Zhidkova et al., 1995; Belkin et al., 1996) . Such splicing, which generally takes place in the cytoplasmic and the extracellular domains, can give rise to a number of subunit isoforms with diverse functional properties (Grinblat et al., 1994; Meredith et al., 1995; Tennenbaum et al., 1995; van der Flier et al., 1995; Belkin, et al., 1996; Roote and Zusman, 1996) .
A laminin-binding integrin complex designated a7f31 has recently been identified and shown to be expressed in skeletal, cardiac, and smooth muscle (Kramer et al., 1991; Song et al. 1992; Collo et al., 1993; Ziober et al., 1993; Yao et al., 1997) . Investigating the function of this receptor has been complicated by the number of alternatively spliced isoforms of the C7 subunit (Song et al. 1992; Collo et al., 1993; Ziober et al., 1993) . In the cytoplasmic domain, two isoforms, A and B, are expressed in a developmentally specific manner in skeletal muscle. Although an a7C variant has been reported in rat myoblasts, its role in development is unknown (Song et al., 1993) . Alternative splicing, in the extracellular domain of this subunit, also produces two muscle-specific developmentally regulated isoforms, designated XI and X2 (Ziober, et al., 1993) . This extracellular alternative splicing occurs in the variable region between the III and IV homology repeat domains near the putative ligand-binding site, where it may define ligand specificity, affinity, or even ligand binding competence (Ziober et al., 1993; Irie et al., 1995; Kamata et al., 1995; Mould, 1996) . In this study we transfected a7-X1 and a7-X2 into MCF-7 cells to characterize the function of each isoform. show that activation of this isoform is regulated in a cell-specific manner.
MATERIALS AND METHODS Cell Culture and Materials
The human breast carcinoma cell line MCF-7 was obtained from the American Type Culture Collection and maintained in DMEM H-16 with 10% fetal bovine serum. The human fibrosarcoma cell line HT1080 was obtained from American Type Culture Collection and maintained in DMEM plus 10% fetal bovine serum. Human plasma fibronectin was purchased from Collaborative Biomedical Products (Bedford, MA). Laminin 1 and the laminin E8 fragment were purified from mouse Engelbreth-Holm-Swarm tumor as described previously (Kramer et al., 1991; Kramer, 1994) . Human laminin 5 was kindly provided by Dr. Robert Burgeson (Cutaneous Biology Research Center, Boston, MA). Human type I collagen was obtained from Collagen Biomaterials (Palo Alto, CA). Antibodies against integrin subunits included the rat anti-human (31 mAb A2B2 and the rat anti-human a5 mAb B2G2, kindly provided by Dr. Caroline Damsky (University of California, San Francisco, CA); mouse anti-human a2 mAb VM1, kindly provided by Dr. Vera Morhenn (SRI International, Menlo Park, CA); the ,B1activating antibody TS2/16, kindly provided by Dr. Martin Hemler (Harvard Medical School, Boston, MA) , and LM230, an anti-human av mAb, kindly provided by Dr. Dean Sheppard (San Francisco General Hospital, San Francisco, CA). Anti-human a3 mAb P1B5 was purchased from Life Technologies (Gaithersburg, MD); rat anti-human a6 mAb GoH3 was purchased from AMAC (Westbrook, ME). The rabbit polyclonal antibody 1211 was prepared in this laboratory against peptide sequences specific to the a7B cytoplasmic region (GTIQRSNWGNSQWEGSDAH; Yao et al., 1996b) . Rat anti-mouse a7 mAbs CA5, CY4, and CY8 were generated in this laboratory as described previously (Yao et al., 1996a) . Goat antirabbit IgG conjugated to horseradish peroxidase (HRP) and ECL kit were purchased from Amersham (Arlington Heights, IL).
Transfection
The construction of a7-X2B cDNA has been described (Yao et al., 1996b) . Primers (5' primer, 5'-CTCGACAGGAAGTGGACCAG-3'; 3' primer, 5'-TGATCCCAAACATGGAATCAG-3') that flank the X1/X2 splice site were used to amplify a 430-bp fragment from C2C12 myoblast mRNA by using reverse transcription-coupled polymerase chain reaction (PCR) and Vent polymerase (with proofreading activity, New England Biolabs, Beverly, MA). This fragment was digested with EspI and ApaI and ligated into the corresponding sites of the a7B cDNA. Positive clones containing the Xl insert were identified by PCR using primers specific for Xl and repeat region IV (5' primer, 5'-GCCAGGGTGGAGCTCTG-3'; 3' primer, 5'-CTATC-CTTGCGCAGAATGAC-3'). The Xl PCR inserts were confirmed by double-stranded DNA sequencing.
Transfection of MCF-7 cells was performed by the calcium phosphate precipitation method (Mammalian Transfection kit, Stratagene, La Jolla, CA). MCF-7 cells at 30% confluency were transfected with 25-30 ,tg of DNA/10-cm plate. Cells were selected in growth medium containing 500 ,tg/ml G418. Individual clones or cell lines were isolated by using cloning rings or by fluorescence-activated cell sorting (FACS). Expression of ca7 in positive clones was verified by Western blot analysis using polyclonal antibody 1211 (Yao et al., 1996b) .
Western Blot
Transfected cell lines and parental cells were solubilized with SDSsolubilization buffer (50 mM Tris, pH 7.5, 0.5% Triton X-100, 1 mM MgCl2, 2 mM phenylmethylsulfonyl fluoride [PMSF], and 1 mM N-ethylmaleimide). Equal amounts of protein were separated by Splicing Regulates c7 Integrin Activation SDS-PAGE on 7.5% gels under nonreducing conditions, transferred to a polyvinylidene difluoride membrane (Millipore, Bedford, MA), and then incubated with a7 polyclonal antibody 1211 followed by goat anti-rabbit IgG-HRP. Migration of the cr7 subunit was determined by using an enhanced chemiluminescence (ECL) detection system (Amersham).
Flow Cytometry
After detachment with 2 mM EDTA, single-cell suspensions of 106 cells/ml were incubated with optimal concentrations of primary antibodies in wash buffer (2% normal goat serum in phosphatebuffered saline [PBS]) for 1 h on ice. Cells were washed three times and incubated with secondary fluorescein-labeled antibodies for 30 min on ice. After washing three times again, the cells were stained with propidium iodide (1 ,ug/ml) to identify nonviable cells. Flow cytometry was performed on a FACScan flow cytometer (Becton Dickinson). Control samples consisted of cells with or without secondary antibody binding. Nonviable cells stained with propidium iodide were eliminated from the analysis. FACS-isolated cell lines were sorted two or three separate times.
Immunoprecipitation of Surface Biotin-labeled Cells
Cells were washed twice with PBS and then labeled with sulfosuccinimidyl-6(biotinamide)-hexanoate (NHS-LC)-biotin (Pierce, Rockford, IL), at 1 mg/ml, in PBS at 4'C for 90 min. To stop labeling, cells were washed twice with 50 mM glycine blocking buffer followed by a 10-min incubation in same buffer. Cells were lysed in PBS with 0.1 M Tris, pH 7.5, 2% Nonidet P-40, 2 mM PMSF, and 1 mM Nethylmaleimide and then precleared with protein A beads. Cell lysates were mixed by rotation with primary antibody and protein A beads for -3 h. Beads were washed with 50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM MgCl2, 0.5% Nonidet P-40, and 0.1% bovine serum albumin (BSA) three times and heated at 100°C in SDS sample buffer for 5 min. The samples were reduced with 2-mercaptoethanol, separated by SDS-PAGE on 7.5% gels, and detected by streptavidin-HRP and ECL.
Cell Adhesion Assay
Microtiter plates (96-well Immulon plates, Dynatech, Chantilly, VA) were coated with matrix proteins or antibodies at the indicated concentrations in PBS for 1 h at 37'C in a humidified atmosphere.
Plates were washed with PBS and incubated with medium containing 0.1% BSA for 60 min in a CO2 incubator to block nonspecific adhesion. Single-cell suspensions were prepared in DMEM containing 0.1% BSA at 4 x 105 cells/ml, added in triplicate to 96-well plates, and then incubated for 30-60 min at 37°C. Nonadherent cells were removed by shaking on a titer-plate shaker (Lab-Line Instruments, Melrose Park, IL) and washed with PBS. Cells were fixed with 1% formaldehyde, stained with 1% crystal violet, and solubilized in 2% SDS; absorbance was then read at 562 nm. Cells bound to collagen (10 ,tg/ml) on a separate plate were used to represent 100% attachment. Background cell adhesion to 1% BSA-coated wells was subtracted from all readings. The effect of specific blocking antibodies was tested by preincubating the cells with the indicated dilutions of purified antibodies on ice for 30 min prior to the assay.
Laminin-Sepharose Affinity Chromatography
Binding of the c7 integrin on laminin E8 was performed as detailed by Kramer (1994) . The E8 fragment of laminin 1 was coupled to CNBr-activated Sepharose to yield 0.5-1.0 mg/ml of packed gel.
Cells were washed twice with PBS and then labeled with NHS-LCbiotin as described above. Labeled cells were then extracted with buffer containing 200 mM octyl ,3-D-glycopyranoside (OPG), in 50 mM Tris-HCl, pH 7.4, 1 mM MnSO4, and 1 mM PMSF for 30-60 min at 4'C. The cell lysate was centrifuged first at 2000 X g to remove nuclei and then at 20,000 x g. One milliliter of supematant was THE a7 INTEGRIN mixed slowly by inversion with -300 ,ul of packed E8-Sepharose overnight. After application of the cell extracts, the column was carefully washed with three to five column volumes of OPG buffer. Finally, the bound a7131 complex was eluted with 10 mM EDTA followed by stabilization with excess Mg2+. Fractions containing eluted integrin subunits were subjected to immunoprecipitation with the appropriate antibodies, separated in an SDS-PAGE gel under reduced and nonreduced conditions, and detected by ECL.
RESULTS

Generation of ai7-X1-and a7-X2-expressing Cell
Lines
We previously reported that the a7 integrin subunit is a laminin-binding integrin that is alternatively spliced in the extracellular domain, producing two isoforms, designated Xl and X2 (Ziober et al., 1993) . This alternative splicing occurs in the variable region between the III and IV homology repeat domains near the putative ligand-binding site (Ziober et al., 1993; Irie et al., 1995; Kamata et al., 1995;  Figure 1 ), which could define ligand specificity, affinity, or integrin activation state. To explore for functional differences between the alternatively spliced extracellular isoforms of a7, we constructed expression vectors for a7-X1 and a7-X2. The cDNAs were then stably transfected into human MCF-7 carcinoma cells, which normally adhere poorly to laminin (Yao et al., 1996b) .
After selection with G418, several a7-X1and a7-X2expressing cell lines were isolated either by FACS sorting or by cloning rings. Two a7-X1-expressing cell lines, X1-A and X1-S3, and two a7-X2 cell lines, X2-A and X2-6, were analyzed further. FACS analysis, using the anti-a7 CY-8 mAb, verified that all cell lines expressed equivalent levels of the integrin (Table 1 ). In addition, Western blotting confirmed that all a7-X1 and a7-X2 MCF-7 cell lines expressed similar levels of the c7 subunit, whereas the parental MCF-7 cells were negative for the receptor (Figure 2A ). Interestingly, a7-X1 displayed a slight decrease in gel mobility when compared with that of a7-X2. Molecular mass calcu- to resolve the a7 subunit from comigrating (31 and transferred to nitrocellulose membranes. When reduced, the a7 subunit separates into its heavy and light chains (Yao et al., 1996b) . The heavy a7 chain is not strongly biotinylated (Yao et al., 1996b) . Proteins were visualized by incubation with streptavidin-HRP and then detected by ECL. The positions of the a7 and 131 subunits are indicated.
lations indicated that this size difference cannot be due to the four additional amino acids encoded by exon Xl as compared with exon X2 (Ziober et al., 1993) . This variation in electrophoretic mobility reflects an -3300-kDa change in molecular mass between a7-Xl and a7-X2, suggesting that there is a conformational difference between the two isoforms. When samples were subjected to SDS-PAGE under reducing conditions, no differences in electrophoretic motility were detected, suggesting that the two a7-Xl and a7-X2 isoforms exist in two conformations that depend on intact disulfide bonds (our unpublished observations). Finally, immunoprecipitation of cell-surface-biotinylated cells verified that both isoforms were expressed at the cell surface and paired with the 131 integrin subunit ( Figure 2B ). Differential Adhesion of a7-X1 and ax7-X2 to Laminin
We compared the ligand binding and specificity of the a7-X1 and a7-X2 isoforms by testing the transfectants in standard adhesion assays using different concentrations of laminin 1 and other ligands. We have shown previously that parental MCF-7 cells express endogenous, potential laminin 1 receptors that are functionally inactive (Yao et al., 1996b) . On laminin 1, a7-X2 transfectants attached with high efficiency; adhesion was dependent on the ligand coating concentration ( Figure 3A ). In previous studies we have shown by using a7-blocking mAbs, that this binding to laminin 1 is specdfic for a7-X2-expressing MCF-7 cells (Yao et al., 1996b) . In contrast, the a7-Xl cell lines, like the parental MCF-7 cells, adhered poorly, even at the highest ligand concentrations. When laminin 1 was replaced with purified laminin 5, both Xl and X2 isoforms failed to bind (our unpublished observations).
The lack of adhesion of the a7-X1 cell lines to laminin 1 suggested that the transfectants might have a general defect in their ability to adhere. To evaluate this possibility, we tested the capacity of the X1 transfectants to bind collagen I. Both Xl and X2 cell lines and parental MCF-7 cells showed similar binding to collagen I, and as expected, antibodies to the a2 collagen receptor completely blocked this adhesion (Figure 3B ). Binding to collagen IV showed similar results (our unpublished results).
We also evaluated whether a7-X1 or a7-X2 could bind fibronectin, because it was reported that the a7 subunit binds to this ligand (Gu et al., 1994) . However, both Xl and X2 transfectants bound equally to fibronectin ( Figure 4) . Blocking antibodies to a5 and av dramatically decreased the ability of the X1 and X2 clones to bind fibronectin, and the combination of a5 and av blocking antibodies totally inhibited binding to fibronectin for all three cell lines. The parental MCF-7 cells adhered to fibronectin with somewhat higher efficiency than the a7 transfectants, which presumably reflects an a7-induced decrease in the fibronectin receptor expression. We have shown a similar down-regulation of 03f31 receptor expression in MCF-7 cells transfected with a7 (Yao et al., 1996b) . Thus, these results show that neither the Xl nor the X2 isoform of the (7 subunit can function as a fibronectin receptor, but cells transfected with either isoform can bind collagen I and IV, indicating that the Xl-transfected cells do not have a defect in adherence even though Xl does not bind laminin 1.
ao7-X1 Integrin Competency for Adhesion and
Spreading
The failure of the Xl isoform to bind laminin suggested that this c7 isoform may be functionally defective. To test for this possibility, we artificially cross- (2 x 104 cells/well) were tested for adhesion to increasing concentrations of laminin 1 as described in MATERIALS AND METHODS. a7-X2 clones showed a dose-dependent adhesion to increasing concentrations of laminin 1. a7-X1 and parental cells bound poorly to laminin at all concentrations. (B) Adhesion of parental MCF-7, a7-X1, and a7-X2 cells to collagen I. Parental MCF-7, Xl, and X2 cells (2 x 104 cells/well) were added to collagen-I-coated plates (5 ,ug/ml). Anti-a2 mAb (VM1) was preincubated with cells at 10 ,ug/ml. Cells bound to collagen type I (at 100 ,tg/ml) were used to indicate 100% adhesion. Adherence of cells in 1% BSA-coated wells was treated as background binding and subtracted. Data are presented as percentages of the total cells added to each well. (A and B) Values are the mean of triplicate wells; bars indicate the SD.
linked the a7-X1 receptor by using an anti-a7 mAb capture assay. In this assay, mAbs directed against the extracellular domain of the a7 subunit were immobilized on culture dishes (see MATERIALS AND METHODS). Transfectants expressing either a7 isoform were allowed to bind the immobilized mAbs. Both a7-X1 and a7-X2 cell lines attached with equal efficiency to the bound anti-a7 mAb ( Figure  5A) ; when anti-X31 mAb was used, both transfectants attached somewhat more efficiently (our unpublished results). Importantly, both Xl and X2 transfectants were induced to spread within 60 min on the immobilized mAbs ( Figure 5 , B and C). These results show that both X2 and Xl, when cross-linked by anti-a7 mAbs, induce an adhering and spreading response typical of functional integrins that requires assembly of the cytoskeleton. In addition, this suggests that although the a7-X1 integrin is unable to engage laminin, it can still function normally in postligand-binding events.
Solubilized a.7-X1 Integrin Fails to Bind Ligand
To determine whether laminin binding by the two isoforms is regulated by their cellular environment, transfectants were processed for ligand affinity chromatography. Receptors were solubilized in detergent and applied to E8-laminin-Sepharose. The presence of a7 in the unbound flow-through fractions and EDTAeluted fractions was assessed by immunoprecipitation with an a7 mAb. Nearly all of the a7-X2 bound to the E8-Sepharose column and was eluted with EDTA (Figure 6) . In contrast, all of the a7-X1 was found in the flow-through and was not detected in the EDTAeluted fractions ( Figure 6 ). Such a result is consistent with the X1 isoform being functionally unable to engage its ligand even when freed from potential cellular regulatory elements.
The a7-X1 Isoform Can Exist in a Ligand-binding Incompetent State
The antibody-capture adhesion assay indicated that the a7-X1 isoform can function as a bridge between the cytoskeleton and the extracellular matrix. However, it fails to explain why this isoform is deficient in binding its ligand. It is well known that many integrins can alternate between activated and inactive states (reviewed in Hemler et al., 1994; Humphries, 1996; Mould, 1996) . This reversible transition to the anti-av mAb (LM230) were preincubated with cells at 10 jig/ml.
Cell adhesion was determined as detailed in Figure 3 .
active state is associated with enhanced ligand-binding affinity and is believed to depend on conformational changes that can be influenced by several factors including stimulatory or activating anti-integrin antibodies and divalent cations (Humphries, 1996) . To A _ \ B test for the possibility that the inability of a7-X1 to bind ligand is a result of the receptor's activation state, we performed adhesion assays to laminin 1 in the presence or absence of ,B1 activating antibodies. Addition of the activating anti-,B1 mAb TS2/16 substantially increased the adhesion to laminin 1 for a7-X1, a7-X2, and parental MCF-7 cell lines (Figure 7) . The most dramatic increase occurred in the ca7-X1 clone, which went from minimal adhesion in the absence of activating antibody to nearly the same level as the a7-X2 cell line in the presence of mAb TS2/16. To identify the integrin complexes responsible for a7-Xl's increased adhesion, we repeated the adhesion assays with TS2/16 and a combination of integrinblocking antibodies. A mixture of blocking antibodies to integrin subunits a2, a3, and a6 completely inhibited TS2/16-activated MCF-7 parental cells from binding to laminin 1 (Figure 7) . In contrast, these same blocking antibodies only slightly reduced the TS2/16activated a7-X1 and a7-X2 cell adhesion to laminin, suggesting that this adhesion was mediated by the O7 subunit. When blocking antibodies to O7 were added to the anti-ca2, -cr3, and -ar6 mAb mixture, adhesion to laminin 1 was completely inhibited for the ca7-X1 and ca7-X2 cell lines (Figure 7) . Similar results were seen when TS2/16 was replaced with the 8A2 activating mAb but not with 9EG7 or 15/7 mAbs (our unpublished results). Results again were similar when these experiments were repeated with the laminin E8 fragment, which contains the c7 binding site (our unpublished results Figure 6 . Detergent-solubilized a7-X2 is able to bind immobilized E8 fragment of laminin 1. Cell-surface biotin-labeled a7-X1and a7-X2-transfected MCF-7 cells were lysed in OPG and processed for ligand affinity chromatography on laminin E8-Sepharose columns. The unbound flow-through material was collected, and after extensive washing of the column, bound integrin was eluted with EDTA (see MATERIALS AND METHODS). The material present in the crude flow-through fraction (lane 1) and the first two fractions eluted with EDTA (lanes 2 and 3) were processed for immunoprecipitation with anti-a7 antibody (1211) and analyzed by SDS-PAGE under nonreduced (top) or reduced conditions (bottom). The positions of the a7 and 11 subunits are indicated. Note that the a7 subunit separates into its heavy and light chains after reduction (Yao et al., 1996b). cells in the presence of anti-a2, -a3, and -a6 adhered at nearly the same level as the untreated a7-X2 transfectants. Thus, these results clearly demonstrate that the failure of the a7-X1 isoform to bind laminin 1 is linked to the activation state of the subunit, which in turn is regulated by the swapping of X2 and Xl inserts.
Mn2" Fails to Activate a7-X1 Adhesion Ligand binding by integrins is dependent on divalent cations (Sanchez-Mateos et al., 1996) . Work by a num- added to laminin 1-coated wells (15 jig/ml) as described under MATERIALS AND METHODS. Where indicated, cells were preincubated with TS2/16 (1.5 ,ug/ml) and combinations of blocking antibodies a2 (VM1), a3 (PlB5), a6 (GoH3), and a7 (CY8), all at 10 ,Lg/ml. Cell adhesion was determined as detailed in Figure 3. ber of investigators has shown that Mn2+, and to a lesser extent Mg2+, can enhance ligand binding by switching the integrin to an activated state via a mechanism believed to be similar to that produced by activating (31 antibodies (Humphries, 1996; Mould, 1996) . When Mn2+ replaced Ca2+/Mg2+ as the divalent cation in adhesion assays, the parental, X1, and X2 cell lines all displayed an increase in adhesion to laminin (Figure 8 ). However, the Mn2+-induced increase in adhesion seen for X1 was inhibited by a mixture of blocking antibodies to integrins a2, a3, and a6, indicating that a7-X1 is resistant to Mn2+-induced activation. As with the TS2/16-treated cells, Mn2+ had only a slight stimulating effect on laminin 1 binding for a7-X2, suggesting that the X2 isoform is already fully activated. These results are consistent with those of the E8-Sepharose chromatography assays, which used detergent-solubilized a7 receptor in the presence of Mn2+.
Regulation of ar7-X1 Ligand Competency Is Cell Type Specific
It is now appreciated that individual integrins can display altered levels of activation depending on the cell type (Gehlsen et al., 1989; Chan and Hemler, 1993) . When we expressed the a7-X1 or a7-X2 variant integrins in MCF-7 cells, the two receptors showed differential binding activity for laminin 1. MCF-7 cells appear to be in the class of host cells that confer a poor level of integrin activation, as indicated by the fact that endogenously expressed a2 and a6 as well as a7-X1 integrins in MCF-7 cells are not capable of binding laminin 1, yet can be fully activated by mAb TS2/16 (Figure 7; Yao et al., 1996b) . For an activation-permissive cell, we chose the HT1080 human fibrosarcoma cells. This cell line expresses a fully functional a6(31 integrin, and adhesion to laminin 1 can be blocked by mAb to a6 (GoH3; Lin et al., 1993; Matter and Laurie, 1994) . For analysis of the cell-type-dependent activation of a7, HT1080 cells were transfected with the a7-XI or a7-X2 isoform, and high-expressing subpopulations of each transfectant were enriched for a7 by flow cytometry after an initial selection with G418. Both the Xland X2-transfected cell lines as well as the parent HT1080 cells showed strong adhesion to laminin (Figure 9 ). However, after treatment with antibodies to a6, the binding of the parental cells was greatly reduced and was completely inhibited in the presence of mAbs to a2, a3, and a6. Although the Xl and X2 transfectants also showed partial blocking of adhesion to laminin in the presence of this mixture of mAbs, were added to laminin 1-coated plates (15 ,ug/ml) as described under MATERIALS AND METHODS. Where indicated, cells were preincubated with combinations of blocking antibodies a2 (VM1), a3 (P1B5), Cr6 (GoH3), and Cr7 (CY8), as in Figure 7 . Cell adhesion was determined as detailed in Figure 3 . substantial binding was still evident, but this binding was abolished when a7 mAb was included. This indicates that in contrast to a7-X1 expression in MCF-7 cells, the integrin's expression in HT1080 cells leads to activation levels that are nearly equivalent to those of the a7-X2 variant.
DISCUSSION
In this study we investigated possible functional differences between Xl and X2, two variants of the a7 integrin subunit that are generated by alternative mRNA splicing in the extracellular domain of the receptor. Our findings show that the alternatively spliced Xl sequence modifies the activation state of the integrin. Whereas the a7-X2 isoform is constitutively active in both cell types, the X1 variant is inactive in MCF-7 cells and fully active in HT1080 cells. This is the first example of cell-type regulation of integrin function that is controlled by alternative splicing in the extracellular subunit domain.
Several a integrin subunits can be alternatively spliced in the extracellular domain between the III and IV N-terminal repeat domains, a region critically important for ligand binding (Ziober et al., 1993; Irie et al., 1995; Kamata et al., 1995; Mould, 1996) . Alternative Splicing Regulates c7 Integrin Activation splicing in Drosophila integrin aPS2 has been shown to alter the binding efficiency of the receptor to the RGDdependent ligands fibronectin and vitronectin (Brown et al., 1989; Zavortink et al., 1993; Roote and Zusman, 1996) . The a6 subunit is also alternatively spliced; however, unlike a7, alternative splicing in a6 results in either exon Xl or a combination of both exons Xl and X2 being spliced in. In contrast to a7, the Xl and X1X2 isoforms of a6 showed no difference in ligand affinity, specificity, or integrin activation. Furthermore, a6-XlX2 is found as a rare mRNA and is probably not physiologically relevant, whereas expression of the a6-X2 isoform has not been detected (Delwel et al., 1995) . Loss of a6-X2 expression probably reflects an evolutionary change in the primordial a7-like gene that is believed to have given rise to a6. It has been suggested that the a3 subunit is also alternatively spliced extracellularly, but the X1 isoform for this subunit has yet to be described (Ziober et al., 1993) . In contrast to a6, both a7 alternatively spliced isoforms Xl and X2 are expressed (Ziober et al., 1993; Wang et al., 1995) . More importantly, this alternative splicing, as shown herein, regulates the a7 receptor's ability to bind ligand.
Since a7-X1 lacks detectable laminin 1 binding activity, we postulated that the a7-X1 variant is expressed in an inactive but presumably reversible conformation, an event that can occur in other integrins. Furthermore, it is now appreciated that individual integrins can display altered levels of activation that are dependent on cell-type specificity (Hemler et al., 1994) . When we expressed the a7-X1 or a7-X2 variant integrins in MCF-7 cells, they showed differential binding activity for laminin 1 (Figure 3A) . Endogenously expressed a2 and a6 integrins are not capable of binding laminin 1, indicating that MCF-7 cells appear to be a class of host cells that confers a poor level of integrin activation (Yao et al., 1996b) . These two integrins also behave similarly when transfected into the nonpermissive K562 cells (Chan and Hemler, 1993; Delwel et al., 1993 Delwel et al., , 1995 Kawaguchi and Hemler, 1993) . In contrast, the a3 subunit (the X2 form), when transfected into K562 cells, is constitutively active for binding laminin 5, as is endogenous a3 in MCF-7 cells (Weitzman et al., 1993; Delwel et al., 1994) . This indicates that the a3 integrin is constitutively active even in cells such as K562 and MCF-7. Thus we consider the a3 integrin to be similar to a7-X2 with regard to its activation state and its sequence homology at the III/IV variable region. In contrast, we suggest that the normally expressed form of a6, the a6-X1 homologue, is cell type specific for activation because of its high homology to a7-Xl. HT1080 human fibrosarcoma cells appear to be an Xl-activation-permissive cell line because they express constitutively activated a6,31. Thus, a7-X1 and a7-X2, when transfected into HT1080 cells, were both active, indicating that activation of the Xl isoform, either for a6 or a7, depends on cell-type specificity (Figure 9 ).
The functional state of an integrin complex is dependent on the conformation of its extracellular domain. A number of factors have been shown to modulate the activity of this extracellular conformation (Humphries, 1996; Mould, 1996) . For example, integrins are sensitive to divalent cation occupancy, and it is well established that cations can regulate integrin activity (Humphries, 1996) . In particular, low concentrations of Mn2' have been shown to induce a high ligand affinity state in integrins . In our studies with the MCF-7 transfectants, Mnk2+ was able to activate only the a2 and a3 integrins and not the a7-X1 isoform. However, Mn2+ did not appear to elevate X2 activity, suggesting that Ca2+/Mg2+ are sufficient for a fully functional a7. This suggests that insertion of the Xl exon appears to alter the conformation of the subunit (which probably accounts for the -3300-kDa molecular mass change in X1 as compared with X2, Figure 2) . Such a conformational change may possibly affect cation binding. Similar studies with a2 showed that cations could not convert the VLA-2 form-O or form-C into a more active form but activating antibodies could (Chan and Hemler, 1993) .
In general, activating antibodies appear to increase the ligand binding competency of integrin molecules. We have shown in this study that the Xl isoform is competent to bind laminin 1 only when activated by mAbs TS2/16 or 8A2 (Figure 7 ; our unpublished results). TS2/16 and 8A2 bind to the same epitope and activate the ,B1 integrin subunit by altering its conformation (Faull et al., 1993; Humphries, 1996) . In contrast, 9EG7 was not able to induce an active conformation in the X1 isoform (our unpublished results). This antibody recognizes an epitope, distinct from that of TS2/16 and 8A2, that is present when /31 is activated by Mn2+ (Bazzoni et al., 1995; Humphries, 1996) . 9EG7 is believed not to define an activation epitope but a ligand-induced binding site that can be induced by cations like Mn2+ (Bazzoni et al., 1995) . Perhaps the failure of 9EG7 to activate the a7-X1 isoform is also due to this isoform's inability to be activated by Mn2 . Antibody 15/7 also failed to activate a7-X1; it too is considered a Mn2+-inducible anti-31 antibody (Picker et al., 1993; Puzon-McLaughlin et al., 1996) . These results and the failure of Xl to bind laminin 1 in the presence of Mn2+ support the notion that the Xl segment is able to alter the conformation of the subunit and inhibit cation binding and ligand adherence.
Comparison of the Xl and X2 alternative splice domains indicates a completely divergent amino acid sequence (Ziober et al., 1993) . Recent observations have indicated that critical residues for ligand-binding activity are clustered in a predicted /3-turn of the C- Figure 10 . Amino acid sequence and secondary structure of the a7-X1 and X2 alternatively spliced domains. The amino acid sequences for X1 and X2 domains were analyzed by using the MacVector program. ,3-sheet conformations are boxed and /3-turn or random coil regions are indicated. Both Xl and X2 have extensive /3-sheet structures; however, Xl has a long random coil motif absent in the X2 that could act as a hinge.
grins a4, a5, and aIIb (Irie et al., 1995; Kamata et al., 1995) . This site (GAPGTYNWKG) is conserved in all a-chains, including a7, and is immediately proximal to the a7 X1/X2 domains. This points to the possibility that the region defined by X1/X2, which directly borders the third repeat domain, may be important in regulating integrin activation. The ,3-turn at this site has been predicted by using several secondary structure prediction methods and from the alignment of the seven repeat domains from 16 different integrin sequences (Tuckwell et al., 1994) . Comparison of the a7-X1 and a7-X2 sequences shows a significant structural difference in the C-terminal half of the variable region ( Figure 10 ). Although the X2 region seems to consist of multiple 13-sheet structures that apparently align with 13-sheet segments in the adjacent IV repeat domain, the Xl region contains a random coil structure of at least 10 residues that begin in the C-terminal half of this variable region. This coil motif in Xl may provide a "hinge-like" structure that may control conformational changes in this putative ligand-binding region of the a7 subunit ( Figure 10 ). Such regulation may ultimately affect ligand-binding competency by turning on or off the subunit's ability to bind to divalent cations. Finally, as shown in this report, this apparent hinge-like structure can be modulated by 131activating antibodies such as TS2/16. How is the activation level of the a7 variants regulated? The observation that 131 activation mAbs can convert the a7-X1 isoform to the "on" state suggests that ligand-binding activity can be controlled by alterations in the partner subunit conformation. Affinity modulation by inside-out signaling via transmembrane conformational transitions has been observed previously (reviewed in Schwartz et al., 1995) . Since the a7 subunit expression is limited to a few highly differentiated tissues and the expression of the X1/X2 isoforms is developmentally regulated, it is possible that the functionality of this integrin needs to be controlled in a tissue-specific manner. Previous work has shown that a7131 is expressed during myoblast differentiation and at the myotendinous and neuromuscular junctions in adult skeletal muscle (Song et al., 1992; Ziober et al., 1993; Martin et al., 1996) . Both isoforms are expressed in myoblasts, but only X2 is detectable in mature muscle, implying that the constitutively active form of the receptor is present at permanent myotendinous junctions and neuromuscular sites (Song et al., 1992; Ziober et al., 1993; Crawley et al., 1996; Martin et al., 1996) . We propose that the regulatable X1 isoform is important during dynamic adhesion situations related to muscle development (motility, fusion, remodeling, repair, and matrix assembly) and that the X2 variant performs more stable adhesion functions (costamers and myotendinous junctions). The function of the two isoforms in skeletal myoblast/ myotube adhesion is currently under investigation. Finally, the ras/raf/MAPK signaling pathway has lately been implicated in regulating the integrin affinity state (Hughes et al., 1997) . Whether this pathway plays an "inside-out" role in regulating the Xl isoform or even in cell-specific activation of this isoform remains to be determined.
